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PURPOSE. The species cross-reactivity of the monoclonal antibodies infliximab, bevacizumab,
and an anti–VEGF-B antibody, 2H10, in humans and rodents was determined.
METHODS. The binding of infliximab to human, mouse, and rat TNF-a, of bevacizumab to
human, mouse, and rat VEGF-A, and of the 2H10 antibody to human, mouse, and rat VEGF-B
was evaluated by ELISA. The sequence of human, mouse, and rat TNF-a and VEGF-A at the
binding sites for infliximab and bevacizumab were compared.
RESULTS. Infliximab bound to human TNF-a, but no binding to mouse or rat TNF-a was
detected between 10 pg/mL and 10 lg/ml. Sequence comparison of the binding site revealed
four changes in mouse and five in rat TNF-a compared with human. Bevacizumab bound
strongly to human VEGF-A, but showed 5-log weaker binding to both mouse and rat VEGF-A.
There was a single amino acid substitution in mouse and rat VEGF-A at the bevacizumab
binding site. The 2H10 antibody displayed a similar binding profile to human, mouse, and rat
VEGF-B.
CONCLUSIONS. The species cross-reactivity of monoclonal antibodies should be determined
prior to their use in preclinical animal models. The 2H10 antibody binds to human, mouse,
and rat VEGF-B making it suitable for testing in rodent models of human disease.
Keywords: biologic, species cross-reactivity, monoclonal antibody, TNF-a, VEGF-A, VEGF-B,
human, mouse, rat
The use of ‘‘biologics’’ for the treatment of human disease isbecoming increasingly common. A number of murine,
chimeric, fully humanized monoclonal antibodies and Fab
fragments have been Food and Drug Administration approved,
and are used in the treatment of diseases, such as breast
cancer,1 head and neck cancer,2 rheumatoid arthritis,3 Crohn’s
disease,4 and systemic lupus erythematosus.5 Biologic anti-
neovascular agents targeting members of the VEGF family of
growth factors have revolutionized the treatment of ocular
conditions, such as proliferative diabetic retinopathy,6 diabetic
macular oedema,7 and neovascular AMD.8,9 Furthermore,
infliximab, an antibody to TNF-a, is used for the treatment of
some forms of noninfectious uveitis.10,11 The development of
additional novel agents could see widespread use of biologics
to treat other ocular conditions.
The high specificity of monoclonal antibodies for their target
epitopes can pose problems if the antibody does not bind to
cross-species homologues. This is particularly important if the
safety and efficacy of a biologic agent is to be evaluated in a
preclinical animal model prior to human use.12 The feasibility
of conducting safety and efficacy testing in animal models
hinges on the species cross-reactivity of the antibody.13 The
vast majority of monoclonal antibodies in clinical use demon-
strate limited species cross-reactivity.14–18
Here, we examined the species cross-reactivity of three
monoclonal antibodies, with applications in ocular diseases, by
ELISA. The binding of bevacizumab (Avastin; Genetech, South
San Francisco, CA, USA), a humanized monoclonal antibody, to
human, mouse, and rat VEGF-A was assessed. The specificity of
infliximab (Remicade; Janssen Biotech, Horsham, PA, USA), a
chimeric monoclonal antibody, for human, mouse, and rat TNF-
a was also evaluated. Finally, the cross-reactivity of a murine
anti–VEGF-B antibody, 2H10, for human, mouse, and rat VEGF-B
was examined.
METHODS
Sources of Antibodies and Growth Factors
Human, mouse, and rat TNF-a and VEGF-A were sourced from
ProspecTany (Rehovot, Israel). Anti-human (AB-210-NA) and
anti-rat (AF-510-NA) TNF-a capture antibody, and anti–VEGF-A
capture antibody (AF564) were obtained from R&D Systems
(Minneapolis, MN, USA). A biotinylated goat–anti-human IgG
antibody (109-065-008) was purchased from Jackson Immuno-
Research (West Grove, PA, USA). Infliximab was purchased
from Johnson and Johnson Health Care Systems (Piscataway
Township, NJ, USA). Bevacizumab was sourced from Genen-
tech (South San Francisco, CA, USA). Antibody-ligand binding
was quantified by ELISA. Two independent experiments were
performed for each ELISA, and representative data depicting
the mean of three technical replicates 6 SD are displayed.
Infliximab ELISA
The binding of infliximab to human, mouse, and rat TNF-a was
assayed using an indirect sandwich ELISA. ELISA plates were
coated with 100 lL 1 lg/mL anti-human or anti-rat/mouse TNF-
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a antibody overnight at 48C. Each plate was washed three times
with 0.05% vol/vol Tween20 (Sigma-Aldrich Corp., St Louis,
MO, USA) in PBS pH 7.4 (wash buffer) and 300 lL blocking
buffer (5% wt/vol skim milk powder [Fonterra, North Adelaide,
Australia], 5% wt/vol sucrose [Merck, Kenilworth, NJ, USA]) in
PBS was added for 1 hour at room temperature. One hundred
microliters of 0.1 lg/mL recombinant human, recombinant
mouse, or recombinant rat TNF-awas added for 1 hour at room
temperature with shaking at 800 rpm. The plate was washed
three times with wash buffer and 100 lL infliximab (100 ng/
mL–100 pg/mL) was applied for 1 hour at room temperature
with shaking at 800 rpm. The plate was washed three times
with wash buffer and bound infliximab was detected with a
biotinylated goat–anti-human IgG antibody, applied at a
1:20,000 dilution in 100 lL for 1 hour at room temperature
with shaking at 800 rpm. The plate was washed three times
with wash buffer and 100 lL 200 ng/mL streptavidin
conjugated to horseradish peroxidase (Life Technologies,
Carlsbad, CA, USA) was added for 20 minutes. The plate was
washed three times with wash buffer and developed with 100
lL TMB solution (BD OptEIA; Becton Dickenson, San Diego,
CA, USA) for 20 minutes, protected from light. Fifty microliters
of 1 M H2SO4 was added and the absorbance at 450 nm was
measured using a plate reader (Molecular Devices, Sunnyvale,
CA, USA).
Bevacizumab ELISA
The binding of bevacizumab to recombinant human, mouse,
and rat VEGF-A was assessed using an indirect sandwich ELISA.
ELISA plates (Nunc, Roskilde, Denmark) were coated with 50
lL VEGF-A capture antibody (1 lg/mL) overnight at 48C. The
plate was washed and blocking buffer was applied as described
above. The plate was washed three times with wash buffer and
50 lL recombinant human, mouse, or rat VEGF-A (10 lg/mL;
R&D Systems, Minneapolis, MN, USA) was added for 1 hour at
room temperature with shaking at 800 rpm. The plate was
washed three times with wash buffer and 50 lL bevacizumab
(10 ng/mL–1 mg/mL) was incubated for 1 hour at room
temperature with shaking at 800 rpm. Bound bevacizumab was
detected with a biotin-conjugated anti-human IgG antibody
(0.13 lg/mL, 50 lL/well), incubated for 1 hour at room
temperature with shaking at 800 rpm. The plate was washed
three times with wash buffer and 50 lL 200 ng/mL streptavidin
conjugated to horseradish peroxidase was added for 20
minutes. The plate was developed and the absorbance read
at 450 nm, as described above.
Anti–VEGF-B mAb ELISA
The binding of the anti–VEGF-B antibody 2H10 to recombinant
human, mouse, and rat VEGF-B was assessed using a direct
sandwich ELISA. An ELISA plate (Nunc, Roskilde, Denmark)
was coated with 50 lL VEGF-B (1 lg/mL in PBS) overnight at
48C. The plate was washed with PBS and 50 lL blocking buffer
(2% BSA in PBS) was applied for 2 hours. The plate was washed
with TPBS (0.05% Tween-20, PBS) and a serial dilution of 2H10
antibody, 100 lL, in antibody buffer (0.5% BSA, TPBS) was
applied for 1 hour. The plate was washed twice with TPBS and
50 lL detection antibody, anti-mouse IgG-HRP (Merck Milli-
pore, Billerica, MA, USA) at 1 lg/mL in antibody buffer was
applied for 30 minutes. The plate was washed three times with
TPBS and developed with 50 lL TMB/E Substrate (Merck
Millipore, Billerica, MA, USA) for 3 minutes. The reaction was
stopped with 25 lL 1M phosphoric acid and the absorbance
read at 450 nm.
Sequence Comparison at Antibody Binding Sites
The sequences of human (ADV31546), mouse (BAF02298.1),
and rat (ADV31545.1) TNF-a, human (NM003376), mouse
(Q00731), and rat (NM031836) VEGF-A, and of human
(NP_001230662.1), mouse (NP_001172093.1), and rat
(NP_446001.1) VEGF-B were obtained from NCBI Protein
Database (in the public domain, http://www.ncbi.nlm.nih.gov/
protein). Sequences were aligned using the AlignX program
(VectorNTI 9.0.0; Thermo Fisher Scientific, Waltham, MA,
USA).
RESULTS
Binding of Infliximab to Human, Mouse, and Rat
TNF-a
Binding of infliximab to human TNF-a was observed above 1
ng/mL antibody concentration (Fig. 1), but the antibody did
not bind to mouse or rat TNF-a at any of the concentrations
tested (10 pg/mL–10 lg/mL). Similar results were observed
when binding was assayed using a direct ELISA (data not
shown).
Binding of Bevacizumab to Human, Mouse, and Rat
VEGF-A
Strong binding of bevacizumab to human VEGF-A was
observed between 1 mg/mL and 10 ng/mL antibody concen-
tration (Fig. 2). Binding to mouse and rat VEGF-A was not
observed below 10 lg/mL. Bevacizumab bound to human
VEGF-A at a 5-log lower concentration when compared with
either mouse or rat VEGF-A. The binding profile of bevacizu-
mab to human, mouse, and rat VEGF-A was similar when tested
by direct ELISA (data not shown).
Binding of 2H10 to Human, Mouse, and Rat VEGF-B
Binding of the 2H10 antibody to human, mouse, and rat VEGF-
B was assessed by direct ELISA. The 2H10 antibody bound to
human, mouse, and rat VEGF-B above 0.01 lg/mL antibody
concentration (Fig. 3). The binding profile of the 2H10
antibody to human, mouse, and rat VEGF-B was similar over
the range of concentrations tested.
FIGURE 1. Binding of infliximab to recombinant human, mouse, and
rat TNF-a. The binding of infliximab to recombinant human, mouse,
and rat TNF-a was assayed by an indirect sandwich ELISA. Infliximab
did not bind to mouse or rat TNF-a at the concentrations tested (100
pg/mL–100 ng/mL). Binding to human TNF-a was observed above 1
ng/ml. Representative data from two independent experiments, with
mean of three technical replicates 6 SD.
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Disparities at the Binding Sites of Infliximab,
Bevacizumab, and 2H10 mAb for Human, Rat, and
Mouse TNF-a, VEGF-A, and VEGF-B, Respectively
Infliximab interacts with 12 amino acids in TNF-a.19 Mouse
TNF-a differs from human at four of these residues, including a
deletion of a serine at position 71 (Table 1). Rat TNF-a is
identical to mouse TNF-a except for an additional substitution
of an arginine for a glutamine at position 67 (Table 1).
The binding site of bevacizumab on VEGF-A consists of 21
residues.20 There is a single amino acid change in the
bevacizumab binding site in mouse and rat VEGF-A compared
with human VEGF-A (Table 2): A serine is substituted for
glutamine at position 88 in rat and mouse VEGF-A.
The 2H10 monoclonal antibody interacts with the VEGF-B
homodimer at 18 residues.21 Human and rat VEGF-B have
identical sequences at the 2H10 binding site, while a proline is
substituted for a serine residue at position 16 in mouse VEGF-B
(Table 3).
DISCUSSION
In this study, we examined the species cross-reactivity of three
monoclonal antibodies. In summary, we found that infliximab
bound strongly to human TNF-a but did not bind to either
mouse or rat TNF-a at the concentrations tested (10 pg/mL–10
lg/mL). Bevacizumab bound to human VEGF-A at a 5-log lower
FIGURE 2. Binding of bevacizumab to recombinant human, mouse,
and rat VEGF-A. An indirect sandwich ELISA was used to assess the
binding of bevacizumab to recombinant human, mouse, and rat VEGF-
A. Bevacizumab demonstrated strong binding to human VEGF-A at the
concentrations tested (10 ng/mL–1 mg/mL). Binding to mouse and rat
VEGF-A was observed above 10 lg/mL antibody concentration. Binding
to mouse and rat VEGF-A was similar to human VEGF-A at five orders of
magnitude higher antibody concentration. These data demonstrate that
bevacizumab at best binds poorly to rodent VEGF-A. Representative
data from two independent experiments, with mean of three technical
replicates 6 SD.
FIGURE 3. Binding of the 2H10 antibody to recombinant mouse,
human, and rat VEGF-B. The binding of the anti–VEGF-B antibody to
human, mouse, and rat VEGF-B was assayed by direct ELISA. The
antibody had a similar binding profile to human, mouse, and rat VEGF-
B. Representative data from two independent experiments, with mean
of three technical replicates 6 SD.
TABLE 1. Sequence Variation in TNF-a at the Infliximab Binding Site
TNF-a Residue
Infliximab Interaction With TNF-a
Human Mouse Rat
67 Q Q R
70 P P P
71 S - -
73 H Y Y
105 T T T
107 E E E
109 A A A
110 E E E
137 N N N
138 R L L
140 D K K
141 Y Y Y
Amino acids in TNF-a interacting with infliximab have been
compared in human, mouse, and rat. Rodent TNF-a differs from
human at a number of residues. Residues that are different in mouse or
rat compared with human have been bolded, - indicates a deletion.
TABLE 2. Sequence Variation in VEGF-A at the Bevacizumab Binding
Site
VEGF-A Residue
Bevacizumab Interaction With VEGF-A
Human Mouse Rat
17 F F F
21 Y Y Y
45 Y Y Y
47 F F F
48 K K K
79 Q Q Q
80 I I I
81 M M M
82 R R R
83 I I I
84 K K K
85 P P P
86 H H H
87 Q Q Q
88 G S S
89 Q Q Q
90 H H H
91 I I I
92 G G G
93 E E E
94 M M M
Amino acids in VEGF-A interacting with bevacizumab have been
compared in human, mouse, and rat. The bevacizumab binding site on
rodent VEGF-A differs from human at a single residue: Glycine 88 is
replaced by serine. Residues that are different in mouse or rat
compared with human have been bolded and underlined.
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concentration than mouse or rat VEGF-A. The 2H10 antibody
displayed a very similar binding profile to human, mouse, and
rat VEGF-B at the range of concentrations tested.
The observed differences in cross-species reactivity of
infliximab and bevacizumab might be explained by sequence
differences at the binding site of their target molecules.
Infliximab interacts with a 12 amino acid sequence on the
human TNF-a molecule.19 Mouse TNF-a differs at four of these
residues and rat TNF-a at five (Table 1). These differences
include the deletion of a serine residue at position 71, which in
combination with the amino acid substitutions may be
responsible for the loss of binding activity to rodent TNF-a.
Bevacizumab interacts with human VEGF-A at 21 residues.20
There is a single amino acid substitution in both mouse and rat
VEGF-A (Table 2). The glycine at position 88 in human VEGF-A
is replaced with a serine in rodent VEGF-A. This small change
at the binding site might explain why bevacizumab binding to
rodent VEGF-A is much weaker, but not completely abolished.
Our results were in keeping with the literature on binding of
bevacizumab to murine VEGF-A.22 Yu et al.23 demonstrated
that bevacizumab bound weakly to murine VEGF-A by Western
blot, but no binding was observed by surface plasmon
resonance. Furthermore, the authors showed that bevacizu-
mab could not neutralize the biological activity of murine
VEGF-A.23
The binding site of the 2H10 antibody on the VEGF-B
homodimer consists of 18 amino acid residues.21 Rat and
human VEGF-B are identical at these residues, whereas proline
is substituted for serine at position 16 in mouse VEGF-B (Table
3). 2H10 exhibited very similar binding profiles to human,
mouse, and rat VEGF-B. Sequence identity at the binding site
explains these findings for human and rat VEGF-B. The single
amino acid substitution in mouse VEGF-B was clearly
insufficient to alter its binding characteristics, given that serine
16 lies outside the direct interaction site and has only two van
der Waals’ contacts with tyrosine at position 49 of the 2H10
mAb.21
Infliximab and bevacizumab unquestionably bind strongly to
human TNF-a and human VEGF-A, respectively. Furthermore,
several reports demonstrate the efficacy of these biologics in
rodent models of ocular disease (Table 4). Thus, TNF-a
inhibition using infliximab has been shown to inhibit laser-
induced choroidal neovascularization in the rat24 as well as the
mouse.25 Infliximab has also been shown to reduce corneal
hemangiogenesis (P < 0.05) and lymphangiogenesis (P < 0.01)
in a murine alkali burn model.26 A study comparing the
antineovascular effect of a number of anti–VEGF-A agents in a
rat model of corneal neovascularisation found that bevacizumab
was the most effective, although all agents tested significantly
inhibited neovascularisation.27 Further work demonstrated that
combination therapy of bevacizumab with etanercept (Enbrel;
Amgen, Thousand Oaks, CA, USA) had a greater antineovascular
effect than monotherapy with either agent alone.28 Of particular
note, both infliximab and bevacizumab have been shown to be
efficacious in models of corneal neovascularization when
applied topically.26,29–31 These results were unexpected, as
whole antibodies penetrate poorly through the human, pig, cat,
and rabbit cornea.32 Although rodent corneas are thinner than
those of the pig or human, which may have influenced
penetration, the major barrier to the penetration of large
molecules through the cornea are the corneal epithelial tight
junctions.33 Nevertheless, the data taken together suggest that
both infliximab and bevacizumab demonstrate functional
species cross-reactivity in rodent models.
The large number of reported studies that have document-
ed a biological effect of human-reactive antibodies in rodent
models, in the absence of specific binding, might point to off-
TABLE 3. Sequence Variation in VEGF-B at the 2H10 mAb Binding Site
VEGF-B Residue
2H10 mAb Interaction With VEGF-B
Human Mouse Rat
16 S P S
17 W W W
18 I I I
21 Y Y Y
25 T T T
26 C C C
27 Q Q Q
48 V V V
49 P P P
62 P P P
79 Q Q Q
81 L L L
83 I I I
87 S S S
88 S S S
90 L L L
101 C C C
102 E E E
Amino acids in VEGF-B interacting with the anti–VEGF-B mAb 2H10
have been compared in human, mouse, and rat. Rat VEGF-B is identical
to human at the binding site for the 2H10 mAb. A proline is substituted
for a serine at residue 16 in mouse VEGF-B (bold).
TABLE 4. Antibody Cross-Reactivity in Animal Models
Condition
Route of
Administration Species Reference
Infliximab
Choroidal neovascularization Intravitreal/intraperitoneal Rat/mouse 24/25
Corneal neovascularization Topical Mouse 26
Asthma Intraperitoneal Rat 34
Ischemia reperfusion injury Intravenous/intraperitoneal Rat 35, 36/37
Otitis media Intravenous Rat 38
Spinal cord injury Subcutaneous Rat 39
Bevacizumab
Corneal neovascularization Subconjunctival injection/topical Rat 27, 28/29–31
Tuberculosis granulomas Intravascular infusion Rabbit 40
Diabetic neuropathy Intraperitoneal Rat 41
Infliximab has been shown to ameliorate a number of inflammatory diseases in rodent models. The antineovascular effect of bevacizumab has
been demonstrated in a number of rodent models of human disease.
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target effects. Such an effect might be mediated through the Fc
portion of the antibody. It is known that intravenous Ig (pooled
polyclonal immunoglobulin) has anti-inflammatory and immu-
nomodulatory effects.42 Of the reports summarized in Table 4,
a single study used normal serum as a negative control.27 The
control in the remainder of the studies was saline, which in
itself is not ideal.
Off-target effects have also been reported with other agents
such as siRNAs. Nonspecific siRNAs showed a comparable
antineovascular effect to targeted siRNAs (against VEGF-A or
VEGF-R1) in a mouse model of choroidal neovascularization.43
Another issue is that inherent variations in animal models may
lead to a false positive result, especially if a small number of
animals are used.
Bevacizumab is a competitive antagonist of VEGF-A and can
bind rodent VEGF-A locally, albeit weakly. The biological effect
of bevacizumab in rodent models might be attributed to the
fact that sufficient bevacizumab was administered to overcome
the deficit in binding rodent VEGF-A. Bevacizumab has been
shown to reduce the serum levels of VEGF-A at very low
concentrations.44 Bevacizumab activity at low concentrations
might explain the antineovascular effects observed in rodent
models, even when binding to rodent VEGF-A is limited.
Finally, we established that the 2H10 antibody displayed a
similar binding profile to human, mouse, and rat VEGF-B by
ELISA and we hypothesize that this antibody is suitable for
testing in preclinical rodent models of human diseases. We
suggest that the species cross-reactivity of monoclonal
antibodies should be tested before being used in animal
models of human disease. We caution that the observation of a
biological effect in animal models, in the absence of specific
binding, may be due to inherent variance in the model, or
caused by an off-target effect of the drug in question.
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